GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2007

Merck & Co’s Japanese Subsidiary Inks Oncology and Metabolic Drug Discovery Deal with MerLion

  • MerLion Pharmaceuticals and Merck Banyu, the Japanese subsidiary of Merck & Co., signed a two-year drug discovery and licensing agreement.

    Under the new collaboration, MerLion and Banyu will identify new drug candidates from MerLion's natural product sample collection utilizing a range of validated targets in oncology and metabolic disease. MerLion will receive upfront payments and predefined milestones and royalties for the licensing of collaborative discoveries.

    MerLion has also extended its four-year agreement based on infectious disease targets with Merck & Co.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »